amfAR Institute for HIV Cure Research: An Interview with Dr. Paul...
Hide & Seek
Paul Volberding, MD, helps create synergy at the amfAR Institute for Cure Research
by Jeannie Wraight
The amfAR Institute for HIV Cure Research was...
Targeting HIV Reservoirs
Hiding Place
One focus of the amfAR 2016 CURE Summit targeted HIV reservoirs
by Jeannie Wraight
This year, amfAR marked World AIDS Day with the 2016 HIV...
Broad Spectrum Antivirals: Part II
Beyond One Bug, One Drug
Broad spectrum antivirals shift the drug model paradigm, part II
by Jeannie Wraight
In the October issue of A&U, Destination: Cure explored...
Broad Spectrum Antivirals: Part I
Spectrum Analysis
Broad spectrum antivirals shift the drug model paradigm
by Jeannie Wraight
The recent spread of emerging pandemic viruses such as Zika and Ebola has increased...
HTVN 702: Vaccine Candidate
Step Forward
Vaccine candidates like HTVN 702 are needed to build momentum
by Jeannie Wraight
If current HIV diagnoses rates persist, about 1 in 2 black men...
Oral Care & Viral Reservoirs
Oral Report
Could something as simple as oral care affect viral reservoirs?
by Jeannie Wraight
Research performed at Case Western found increased levels of HIV in the...
Orphaned Vaccines
Sometimes viewing a complex issue in its most simplistic form can help us to understand where a problem lies. HIV is a virus that...
4 CROI Briefs
Another year of the Conference on Retroviruses and Opportunistic Infections (CROI 2016) has come to pass. Here are a few less publicized but important...
Interferon & HIV
Luis J. Montaner DVM, D.Phil, of the Wistar Institute in Philadelphia, Pennsylvania has been studying the effects of interferon on HIV DNA and its...
AR-12: One Drug Candidate, Many Possibilities
One Drug, Many Possibilities
A new agent may assist in the fight against HIV and other viruses
by Jeannie Wraight
Every once in a while I come...